Stop-and-go treatment for widely spread nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a 'stop and go' treatment plan for people with widely spread nasopharyngeal cancer. It aims to see if taking breaks from treatment can help manage side effects while still controlling the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have nasopharyngeal cancer that has spread to more than 5 spots or more than 2 organs.
- You are able to take care of yourself (ECOG score 0-2) and your doctor expects you to live at least 6 more months.
- You have at least one tumor that can be measured on a scan.
- You agree to use effective birth control during the study and for 12 months after treatment.
- If you've had chemotherapy or radiation before, it must have been at least 6 months ago.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This trial tests a new treatment for people with advanced nasopharyngeal cancer that has spread (stage IVb) and who have not yet had chemotherapy. It aims to see if the experimental treatment is safe and effective as a first option.
This trial tests a combination of low-dose radiation and immunotherapy (drugs that help your immune system fight cancer) for people with nasopharyngeal cancer that has spread to other parts of the body and who cannot receive chemotherapy. The goal is to see if this treatment can help control the cancer and improve outcomes.
This trial studies whether gemcitabine plus camrelizumab plus apatinib works better than cisplatin alone for people with recurrent or metastatic non-keratinizing nasopharyngeal cancer. It’s meant for people who haven’t had prior whole-body (systemic) treatment for the returning/spreading cancer.
This trial tests a combination of two types of radiation therapy (standard SBRT and low-dose radiation) along with chemotherapy and an immunotherapy drug (PD-1 antibody) for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this combination can better control the cancer.
This trial tests whether combining an immunotherapy drug (PD-1 inhibitor) with chemotherapy and radiation can help treat nasopharyngeal cancer that has spread to the lungs. It is for people whose cancer returned more than six months after initial treatment and who haven't had immunotherapy before.
Hear when a new Metastatic Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.